MDS: unraveling the mystery.

Published

Journal Article

In this issue of Blood, Sekeres et al report a phase 2 study of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). High overall response and duration of response supports the concept of combination, multitargeted approaches rather than traditional chemotherapeutics for this disease.

Full Text

Duke Authors

Cited Authors

  • Rizzieri, DA

Published Date

  • December 13, 2012

Published In

Volume / Issue

  • 120 / 25

Start / End Page

  • 4906 - 4908

PubMed ID

  • 23243154

Pubmed Central ID

  • 23243154

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2012-09-452755

Language

  • eng

Conference Location

  • United States